Key facts
- Bayer is seeking approval for a $7.25 billion settlement to resolve Roundup cancer lawsuits.
- The settlement aims to resolve nearly all of the approximately 65,000 claims in U.S. courts.
- Payouts under the settlement range from $10,000 to $165,000 for individuals diagnosed with non-Hodgkin lymphoma after Roundup exposure.
- Bayer denies the claims and states that studies show Roundup's key ingredient, glyphosate, is safe.
- The World Health Organization's International Agency for Research on Cancer determined glyphosate was a probable carcinogen in 2015, while the EPA found it not likely to cause cancer in humans.
Bayer's Monsanto unit is undergoing a critical court hearing in Missouri to determine the fate of a $7.25 billion settlement designed to resolve tens of thousands of lawsuits alleging that its Roundup weedkiller causes cancer. Judge Timothy Boyer is presiding over the hearing, where he will consider objections from some plaintiffs' attorneys who argue the proposed framework is insufficient for their clients, alongside arguments from those who believe it offers the best path to compensation.
The litigation has been a significant financial and reputational burden for Bayer since its 2018 acquisition of Monsanto, costing billions and impacting its stock price. Investors view the resolution of these claims as a key indicator of Chief Executive Bill Anderson's turnaround strategy. A prior $10 billion settlement in 2020 addressed many existing claims but left Bayer vulnerable to future litigation.
The current settlement, announced in February, aims to cover approximately 65,000 claims in U.S. state and federal courts. Bayer maintains that Roundup's active ingredient, glyphosate, is safe and does not cause cancer, citing decades of studies. The proposed payouts range from $10,000 to $165,000, varying based on cancer severity, age at diagnosis, and exposure context (home or work).
Supporters of the deal argue it provides a guaranteed compensation route for cancer patients, especially after a recent Supreme Court ruling favored Monsanto, potentially weakening plaintiffs' legal standing. Opponents, however, contend the settlement offers inadequate compensation and is designed to ensnare both current and future claimants. A Monsanto spokesman stated the company believes the class settlement, supported by plaintiffs' counsel for tens of thousands of potential class members, is fair and warrants final approval.
The debate over glyphosate's carcinogenicity has been ongoing since 2015 when the WHO's International Agency for Research on Cancer classified it as a probable carcinogen. In contrast, the U.S. Environmental Protection Agency (EPA) concluded in 2017 that glyphosate is not likely to cause cancer in humans under typical exposure conditions. The EPA does not mandate a cancer risk warning on Roundup's label and is expected to release an updated human health risk assessment for glyphosate in late 2026. Bayer's legal position was bolstered by a Supreme Court ruling concerning the adequacy of Roundup's warning label, which challenged a central argument in many of the lawsuits.